KRAS status and resistance to epidermal growth factor receptor tyrosine-kinase inhibitor treatment in patients with metastatic colorectal cancer: a meta-analysis. - Wikidata - wikimedia - TriplyDB

KRAS status and resistance to epidermal growth factor receptor tyrosine-kinase inhibitor treatment in patients with metastatic colorectal cancer: a meta-analysis.

KRAS status and resistance to epidermal growth factor receptor tyrosine-kinase inhibitor treatment in patients with metastatic colorectal cancer: a meta-analysis.

http://www.wikidata.org/entity/Q35231369

about

Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers Molecular subtypes of colorectal cancers determined by PCR-based analysis.The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer.

P2860

Q26781362-6145B0BE-AD3F-4092-BFC9-93354FB982AE Q37735649-55369175-4A03-4462-BAC7-E905AFB4CA59 Q55252442-A3E53F49-1F66-4C48-949F-5ACA224CC676

P2860

KRAS status and resistance to epidermal growth factor receptor tyrosine-kinase inhibitor treatment in patients with metastatic colorectal cancer: a meta-analysis.

http://www.wikidata.org/entity/Q35231369

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

KRAS status and resistance to ...... ectal cancer: a meta-analysis.

@ast

KRAS status and resistance to ...... ectal cancer: a meta-analysis.

@en

type

label

KRAS status and resistance to ...... ectal cancer: a meta-analysis.

@ast

KRAS status and resistance to ...... ectal cancer: a meta-analysis.

@en

prefLabel

KRAS status and resistance to ...... ectal cancer: a meta-analysis.

@ast

KRAS status and resistance to ...... ectal cancer: a meta-analysis.

@en

P1433

Q35231369-686269C4-EB75-4235-9A90-AD597A4716FD

P1476

Q35231369-C0D67BF0-C829-458C-9EDF-883A3814D303

P2093

Q35231369-07741BFD-4C8F-49E3-9C9F-BCED9F105E8B

Q35231369-13AE2A54-CA54-48C6-85BD-A1CA3826AFEE

Q35231369-25A5D7BC-B943-4B1C-A81F-F88E8F7B305B

Q35231369-B5196252-670F-44A0-B5D9-651C2002C3A8

Q35231369-EDBF7A22-3E58-4F1A-9DEB-A5B4C53586F3

Q35231369-EE20DC94-4C5A-4E93-9280-E12B6972DBED

Q35231369-F02B9586-22AD-4EF5-9320-FD7C8C88C16D

P2860

Q35231369-00660570-FB37-4BDE-A2FA-616B11B736FB

Q35231369-05C11B14-B352-4F4B-B57A-F08476DAFCA1

Q35231369-20E7E454-359F-411C-B743-D548D5C2924D

Q35231369-2B83E7E3-3411-49A5-A41B-F287CB2B3711

Q35231369-307BCB08-2AB2-477C-8A3B-A6BC052D443F

Q35231369-41A8BE98-4742-425E-B402-00B3400459D8

Q35231369-41B89BD1-9F0E-4C23-B794-B6CE73E0C7DE

Q35231369-4933FFE5-7617-4126-8758-F2FA3EC72D45

Q35231369-50154577-DC13-4BDC-8371-ECF9CAD82BEA

Q35231369-50C6AE60-97C4-4DF2-B702-527C162690A8

P304

Q35231369-30E32956-F789-4B36-8E1A-49AD7A79A65D

P31

Q35231369-255f617f-422e-4dd6-a337-917cd8f1bf45

Q35231369-A27651C7-A456-4868-BACD-50FCA89F7DA9

P356

Q35231369-DDBA0144-B893-447C-B146-26C39777762A

P433

Q35231369-A7EA77B9-5D0D-4E98-95E8-411B437A9ABF

P478

Q35231369-403795E6-1210-4834-AE46-C9EE5A384CC8

P577

Q35231369-F228B0DF-257E-4544-A13F-D469A5666676

P698

Q35231369-F59CFD33-E501-4713-AC41-817F83AEBB07

P921

Q35231369-6DBBE894-8C37-4BDD-99D5-182F3CED2263

P356

P1433

Colorectal Disease

P1476

KRAS status and resistance to ...... ectal cancer: a meta-analysis.

@en

P2093

F Hou

http://www.w3.org/2001/XMLSchema#string

J Liu

http://www.w3.org/2001/XMLSchema#string

J Ren

http://www.w3.org/2001/XMLSchema#string

Q Li

http://www.w3.org/2001/XMLSchema#string

Q Shi

http://www.w3.org/2001/XMLSchema#string

W Li

http://www.w3.org/2001/XMLSchema#string

W Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials

Bias in meta-analysis detected by a simple, graphical test

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

PIK3CA mutation is associated with poor survival among patients with metastatic colorectal cancer following anti-EGFR monoclonal antibody therapy: a meta-analysis.

Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis

Quantifying heterogeneity in a meta-analysis

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy.

Systemic therapy for colorectal cancer.

P304

O370-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/CODI.12749

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2014-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25155261

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer